Stocks Health care AKBA
NASDAQ · Health careAkebia Therapeutics, Inc. (AKBA)
Akebia Therapeutics, Inc. brought in $197.2M of revenue over the twelve months to September 30, 2026, down 12.4% from a year earlier. It posted a net loss of $44.6M. Operating cash flow minus capital spending left $67.7M of free cash flow in fiscal 2025. At September 30, 2026 it held $159.3M in cash against $50.3M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Akebia Therapeutics, Inc.
- Net worth
- Akebia Therapeutics, Inc. has a market value (market cap) of $147.6M at the latest share price, and shareholders' equity of $20.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $236.2M (+47.5% year on year), with a net loss of $5.3M. Over the 12 months to September 30, 2026: revenue $197.2M, net loss $44.6M.
- Cash flow
- In fiscal 2025 operations brought in $68M of cash; after $291K of capital spending, free cash flow was $67.7M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Akebia Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Akebia Therapeutics, Inc. does
Akebia Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AKBA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $236.2M | -$5.3M | -$0.02 | $67.7M |
| 2024 | $160.2M | -$69.4M | -$0.33 | -$40.7M |
| 2023 | $194.6M | -$51.9M | -$0.28 | -$23.4M |
| 2022 | $292.5M | -$94.2M | -$0.52 | -$73.3M |
| 2021 | $211.7M | -$282M | -$1.70 | -$253M |
| 2020 | $294.6M | -$384.8M | -$2.78 | -$110.7M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where AKBA ranks in Health care
Latest SEC filings
What Akebia Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 37% to $36.9M versus the same quarter last year; diluted EPS -$0.05 versus $0.00.
- November 5, 2026
- October 23, 2026
- October 14, 2026
- August 5, 2026
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue fell 21% to $49.1M versus the same quarter last year; diluted EPS -$0.03 versus $0.00.
- August 5, 2026
- June 30, 2026
- June 22, 2026
- May 12, 2026Passive stake (5% or more) SCHEDULE 13G
What is AKBA worth? A DCF from its reported cash flow
Insider trades
What the people running Akebia Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 6, 2026 | Butler John P.CEO and President, Director | Exercised options | 350,000 | $220.5K |
| June 29, 2026 | Ostrowski ErikSVP, CFO, CBO & Treasurer | Soldpre-planned (10b5-1) | 56,019 | $62.2K |
| June 17, 2026 | Zumwalt Leanne MDirector | Received as pay | 35,700 | - |
| June 17, 2026 | Rogers Michael WDirector | Received as pay | 35,700 | - |
| June 17, 2026 | Adams AdrianDirector | Received as pay | 35,700 | - |
| June 17, 2026 | Smith CynthiaDirector | Received as pay | 35,700 | - |
| June 17, 2026 | Wolf MylesDirector | Received as pay | 35,700 | - |
| June 17, 2026 | Frieson RonDirector | Received as pay | 35,700 | - |
Who owns AKBA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
Largest institutional holders
Insiders
12 insiders reported holding 7,842,773 shares in total, about $4.2M at the last price.
| Holder | Shares |
|---|---|
| Butler John P.CEO and President, Director | 3,718,564 |
| Burke Steven KeithSVP, Chief Medical Officer | 948,432 |
| Ostrowski ErikSVP, CFO, CBO & Treasurer | 616,616 |
| Rucci Carolyn M.SVP, Chief Legal Officer | 588,378 |
| Grund NicholasChief Commercial Officer | 561,750 |
| Malabre Richard CSVP, Chief Accounting Officer | 299,390 |
| Adams AdrianDirector | 236,200 |
| Rogers Michael WDirector | 197,429 |
| Smith CynthiaDirector | 196,633 |
| Wolf MylesDirector | 169,081 |
Questions about AKBA
What does Akebia Therapeutics, Inc. do?
Akebia Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as AKBA. Its shares trade on NASDAQ under the ticker AKBA.
What is Akebia Therapeutics, Inc.'s net worth?
Akebia Therapeutics, Inc. has a market value (market cap) of $147.6M at the latest share price, and shareholders' equity of $20.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Akebia Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $44.6M on revenue of $197.2M.
How much revenue does Akebia Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Akebia Therapeutics, Inc. reported revenue of $197.2M. That is 12.4% less than a year earlier.
When did Akebia Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Akebia Therapeutics, Inc.'s next earnings report?
Akebia Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare AKBA with
Follow AKBA
Get an email when Akebia Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Akebia Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.